Fig. 4

The combination of SNH and BBR eradicated S. aureus persister cells. a MRSA ATCC33591 persister cells treated with SNH (64 μg/mL, MIC), BBR (512 μg/mL, MIC) or SNH-BBR combination for 24 h. b VISA Mu50 persister cells treated with SNH (64 μg/mL, MIC), BBR (1024 μg/mL, 2MIC) or SNH-BBR combination for 24 h. c Clinical MRSA CCPM(A)-P-0116173 persister cells treated with SNH (64 μg/mL, 2MIC), BBR (256 μg/mL, 2MIC) or SNH-BBR combination for 24 h. d Clinical MRSA CCPM(A)-P-010850 treated with SNH (64 μg/mL, 2MIC), BBR (128 μg/mL, 2MIC) or SNH-BBR combination for 24 h. e Clinical MRSA CCPM(A)-P-01012 treated with SNH (64 μg/mL, MIC), BBR (128 μg/mL, 2MIC) or SNH-BBR combination for 24 h. The y-axis starts at the value of the minimum detection limit. Asterisks (*) denote statistical significance compared with untreated control, while hash marks (#) indicate significant differences between the groups of SNH-BBR combination and BBR alone, as determined by one-way ANOVA followed by Turkey’s multiple-comparison test (****, P < 0.0001; ####, P < 0.0001)